logo

For the Inventor, By the Inventor

Palo Alto, CA, United States of America

Eiger Biopharmaceuticals, Inc.


USPTO Granted Patents = 13


Trademarks = 3

Forward Citations = 43

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal David A Cory (6 out of 7 patents)

silverMedal Xiaofeng Xiong (6 out of 7 patents)

bronzeMedal Jeffrey S Glenn (4 out of 39 patents)

4.  Ingrid Choong (4 out of 17 patents)

5.  Debra Odink (2 out of 4 patents)

6.  Christine M N Smith (2 out of 2 patents)

7.  Tracey L McLaughlin (2 out of 10 patents)

8.  Colleen M Craig (2 out of 11 patents)

9.  Patrick Gosselin (2 out of 2 patents)

10.  Aimesther Betancourt (2 out of 2 patents)

11.  Eduardo Bruno Martins (1 out of 2 patents)


13 patents:

1. 12029819 - Pharmaceutical compositions comprising lonafarnib and ritonavir (2024-07-09),
2. 11793793 - Treatment of hepatitis delta virus infection (2023-10-24),
3. 11738086 - Methods of using buffered formulations of exendin (9-39) (2023-08-29),
4. 11571403 - Methods for the treatment of non-alcoholic steatohepatitis (2023-02-07),
5. 11517532 - Methods of treating hepatitis delta virus infection (2022-12-06),
6. 11311519 - Treatment of hepatitis delta virus infection (2022-04-26),
7. 11116820 - Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives (2021-09-14),
8. 11020484 - Buffered formulations of exendin (9-39) (2021-06-01),
9. 10953072 - Treatment of hepatitis delta virus infection with interferon lambda (2021-03-23),
10. 10828283 - Treatment of hepatitis delta virus infection (2020-11-10),
11. 10653753 - Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives (2020-05-19),
12. 10588880 - Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis (2020-03-17),
13. 10076512 - Treatment of hepatitis delta virus infection (2018-09-18),
Company Overview
Eiger Biopharmaceuticals, Inc. is a biopharmaceutical company based in Palo Alto, California, focused on the development of innovative therapies for rare diseases. The company specializes in advancing treatments that target unmet medical needs, particularly in the fields of infectious diseases and genetic disorders. Eiger's research emphasizes the use of proprietary drug candidates and novel therapeutic approaches, aiming to improve patient outcomes through rigorous scientific exploration and clinical development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Eiger Biopharmaceuticals, Inc. USPTO Patent Assignee Logo
13 Patents

#134 in Palo Alto, CA

#5,656 in California

#23,838 in US

#45,039 in the World

Palo Alto, CA (US)
Palo Alto, CA, United States of America

Eiger Biopharmaceuticals, Inc.

Forward Citations = 43

11 inventors:

goldMedal David A Cory (6 out of 7 patents)

silverMedal Xiaofeng Xiong (6 out of 7 patents)

bronzeMedal Jeffrey S Glenn (4 out of 39 patents)

4.  Ingrid Choong (4 out of 17 patents)

5.  Debra Odink (2 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Eiger Biopharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/eiger-biopharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…